Overcoming resistance to BRAF(V600E) inhibition in melanoma by deciphering and targeting personalized protein network alterations

BRAF(V600E) melanoma patients, despite initially responding to the clinically prescribed anti-BRAF(V600E) therapy, often relapse, and their tumors develop drug resistance. While it is widely accepted that these tumors are originally driven by the BRAF(V600E) mutation, they often eventually diverge a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:NPJ Precis Oncol
Main Authors: Vasudevan, S., Flashner-Abramson, E., Alkhatib, Heba, Roy Chowdhury, Sangita, Adejumobi, I. A., Vilenski, D., Stefansky, S., Rubinstein, A. M., Kravchenko-Balasha, N.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8192524/
https://ncbi.nlm.nih.gov/pubmed/34112933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41698-021-00190-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados